ArticleCancers2021

Efficacy of BRAF and MEK Inhibition in Patients with BRAF-Mutant Advanced Melanoma and Germline CDKN2A Pathogenic Variants.

Francesco Spagnolo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.